Education
About Us
Working with TipRanks
Follow Us
Nanovibronix (NAOV)
:NAOV
NAOV Stock Chart & Stats
$5.88
$0.01(2.03%)
At close: 4:00 PM EST
$5.88
$0.01(2.03%)
Day’s Range― - ―
52-Week Range$4.71 - $162.50
Previous CloseN/A
Volume412.44K
Average Volume (3M)2.06M
Market Cap
$5.80M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.72
Shares Outstanding1,011,102
10 Day Avg. Volume87,531
30 Day Avg. Volume2,055,374
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NanoVibronix News
NAOV FAQ
What was Nanovibronix’s price range in the past 12 months?
Nanovibronix lowest stock price was $4.71 and its highest was $162.50 in the past 12 months.
What is Nanovibronix’s market cap?
Nanovibronix’s market cap is $5.80M.
When is Nanovibronix’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nanovibronix’s earnings last quarter?
Nanovibronix released its earnings results on Nov 16, 2021. The company reported -$562.716 earnings per share for the quarter, missing the consensus estimate of N/A by -$562.716.
Is Nanovibronix overvalued?
According to Wall Street analysts Nanovibronix’s price is currently Overvalued.
Does Nanovibronix pay dividends?
Nanovibronix does not currently pay dividends.
What is Nanovibronix’s EPS estimate?
Nanovibronix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanovibronix have?
Nanovibronix has 1,011,102 shares outstanding.
What happened to Nanovibronix’s price movement after its last earnings report?
Nanovibronix reported an EPS of -$562.716 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.162%.
Which hedge fund is a major shareholder of Nanovibronix?
Currently, no hedge funds are holding shares in NAOV
Company Description
Nanovibronix
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Technical Analysis
Ownership Overview
12.96%
Insiders
0.56% Mutual Funds
26.34% Other Institutional Investors
86.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---